| Verified against primary record | |
| Registration requirement | Before the first participant is enrolled, in a registry meeting international standards; ethics committee approval does not satisfy it[1] |
|---|---|
| Charging, United States | Permitted only with prior written authorisation, limited to direct cost recovery, with the calculation reviewed by an independent accountant[2] |
| Charging, European Union | The subject does not bear the cost of investigational products or protocol-required procedures, unless national law provides otherwise[3] |
| Independently reported | |
| How often it happens | Cross-border trial participation within the European Union occurs but very rarely, though most surveyed stakeholders said access abroad is needed[4] |
| Bands apply only to the rows beneath them. The charging rules are domestic rules of the trial’s own jurisdiction; neither addresses a participant who has travelled from another country. | |
Clinical trials abroad describes travel undertaken to join a clinical trial in another country. It is a different transaction from buying treatment, and the clearest marker of the difference is money: in a properly conducted trial the participant does not pay a price for the investigational product.
What counts as a trial, and the registration rule
A clinical trial, for registration purposes, is a study that prospectively assigns human participants or groups to one or more health-related interventions, covering drugs, surgical procedures, devices and behavioural treatments, across all phases. Registration is treated as a scientific, ethical and moral responsibility; trials should be registered before the first participant is recruited; a trial need be registered only once, in a primary registry meeting international standards; and requirements differ by country, so those running a trial must check the requirements in each country involved.[5] The platform that aggregates these registries is not itself a registry, and registration means publishing an internationally agreed set of information about a trial’s design, conduct and administration on a public website run by a registry meeting the relevant standards.[6]
Journal editors enforce the rule through publication. Trials must be registered at or before the time of first patient consent for enrolment and before the first participant is enrolled; acceptable registries are those in the aggregating network that include the minimum data set, plus one national registry; registrations are inadequate where fields are missing, entries are uninformative or records are not publicly accessible; and ethics committee approval does not satisfy the registration requirement. Failure to register prospectively risks the trial being inadmissible for publication, and retrospective registration does not serve the purposes of registration.[1] An unregistered study offered to a travelling patient is therefore one whose results may never be publishable.
The ethical requirements for research across borders
The principal ethical instrument addresses cross-border research directly. Researchers must consider the ethical, legal and regulatory norms of the country of origin and of the country where the research is performed as well as international norms, and no national or international requirement should reduce protections for participants. Internationally collaborative research must be approved by research ethics committees in both the sponsoring and the host country, and local norms cannot reduce the Declaration’s protections. The distribution of benefits, risks and burdens must be considered in light of structural inequities, with community engagement before, during and after the research. Research with vulnerable groups is justified only where it responds to their health needs and they stand to benefit. The protocol must describe post-trial provisions, and sponsors and researchers must arrange in advance for participants who still need a beneficial and reasonably safe intervention, with participants told of those provisions when consenting. Participants harmed by research must receive appropriate compensation and treatment. Research must be registered in a publicly accessible database before the first participant is recruited, and negative and inconclusive results must be made publicly available.[7]
Who pays, and why it is the decisive test
In European Union law the default is that the trial subject does not bear the cost of investigational medicinal products, auxiliary medicinal products, the devices used to administer them, or procedures the protocol specifically requires. The rule preserves member states’ competence over health policy and the organisation and delivery of care, and applies unless the law of the member state concerned provides otherwise, so national law can displace it.[3]
In United States law charging is possible but tightly bounded. A sponsor must obtain prior written authorisation from the regulator before charging for an investigational drug, and the authorisation may be withdrawn. To charge within a clinical trial the sponsor must show that the drug has potential clinical benefit providing a significant advantage over available products, that the trial data would be essential for initial approval or would support a significant labelling change, and that the trial could not be conducted without charging because the drug’s cost is extraordinary to the sponsor. Only direct costs are recoverable, meaning costs specifically and exclusively attributable to providing the drug such as per-unit manufacturing cost, acquisition cost and shipping and handling; indirect costs tied to commercial-scale production, research and development or administration are not. The sponsor must document its calculation with a statement that an independent certified public accountant reviewed and approved it, and an authorisation for expanded access lasts one year unless a shorter period is set.[2]
That is the cleanest available line between a trial abroad and an unproven treatment sold abroad. Audited recovery of the direct cost of manufacturing a dose, authorised in advance, is a different transaction from a clinic quoting a market price for an unapproved product. Neither framework should be summarised as a flat prohibition on charging participants, because both have exceptions, and neither framework addresses a participant who has travelled from another country.
Is a trial participant a medical tourist?
No authoritative body was found that classifies travel to join a trial as medical tourism, and the research literature treats it as a separate category because the traveller is a research participant rather than a purchaser of care. The work that exists uses the language of cross-border access to clinical trials, and finds that such participation within the European Union does occur but very rarely, even though 92 per cent of survey respondents said access abroad is needed; that the main motivation is lack of access to treatment at home; that stakeholders identified the logistical and financial burden on patients as the biggest challenge and disagreed about who should bear financial and organisational responsibility; and that most interviewees felt patients ideally should not have to travel to reach experimental treatment.[4]
The definitional backdrop is a widely cited distinction between medical tourism, as travel across international borders intending to receive medical treatment, and medical travel for care deemed essential by a health professional, with the observation that national quality-control measures do not apply across borders, that there are no international quality standards, and that legal frameworks need to clarify liability for adverse events while insurance coverage for complications may be unavailable.[8] That source does not address research participation, which is part of why the category remains unsettled.
See also
- Experimental Treatment, and why charging a market price for an unapproved product is not a trial
- Compassionate Use of Medicines, the route for patients who cannot join a trial
- Medical Travel for Unavailable Treatments, the motivation this literature identifies
- Medical Tourism, the definitional boundary a trial participant sits outside
References
- International Committee of Medical Journal Editors. Clinical trial registration, ICMJE Recommendations. No date on the page. Verified against primary record: the recommendation was opened and the timing requirement, acceptable registries, adequacy conditions and the statement about ethics approval read. Retrieved 10 October 2026.
- United States Code of Federal Regulations, 21 CFR 312.8, charging for investigational drugs under an investigational new drug application. Read at the Legal Information Institute reproduction. Verified against primary record only to the extent that this reproduction of the regulatory text was opened and read; the page carries no authority citation or amendment date and the text should be confirmed on the official register before being relied on. Retrieved 10 October 2026.
- European Parliament and Council. Regulation (EU) No 536/2014, Article 92. Verified against primary record: the article text was opened and the default cost rule and its national-law exception read. Retrieved 10 October 2026.
- Lalova T, Padeanu C, Negrouk A, Lacombe D, Geissler J, Klingmann I, Huys I. Cross-border access to clinical trials in the EU: exploratory study on needs and reality. Frontiers in Medicine 2020;7:585722. Independently reported: the retrievable text was at abstract level, and only abstract-level findings are attributed here. Retrieved 10 October 2026.
- World Health Organization. Clinical trials: questions and answers. 16 January 2020. Verified against primary record: the page was opened and the definition, the registration timing and scope, and the statement that country requirements differ read. Retrieved 10 October 2026.
- World Health Organization. International Clinical Trials Registry Platform. Verified against primary record: the page was opened and the statement that the platform is not itself a registry, and its description of what registration means, read. Retrieved 10 October 2026.
- World Medical Association. WMA Declaration of Helsinki: ethical principles for medical research involving human participants. 2024 revision, adopted October 2024; page dated 19 October 2024. Verified against primary record: the Declaration was opened and the provisions on dual-country norms and approvals, structural inequities, vulnerable groups, post-trial provisions, compensation, registration and publication read. Retrieved 10 October 2026.
- Ruggeri K, Zalis L, Meurice CR, Hilton I, Ly T-L, Zupan Z, Hinrichs S. Evidence on global medical travel. Bulletin of the World Health Organization 2015;93(11):785-789. Verified against primary record: the article was opened and the definitional distinction and the statements on cross-border quality control and liability read. It does not address unproven or experimental treatment. Retrieved 10 October 2026.
Sourcing note: the United States charging regulation was read in a reproduction of the regulatory text rather than on the official register, which is recorded in its reference. The finding that no authority classifies trial-related travel as medical tourism is a negative result from searching the regulatory, intergovernmental and research literature, and is stated as such. The World Health Organization’s guidance on best practices for clinical trials was consulted at publication-record level only and is not cited, because no specific requirement could be attributed to it without opening the document itself.